Cantargia (OMX: CANTA)

Currency in SEK

Last close As at 28/03/2023

SEK6.29

0.00 (0.00%)

Market capitalisation

SEK1,108m

Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.

Increasing understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Goran Forsberg

    CEO

Balance Sheet

Forecast net cash (SEKm)

119.4

Forecast gearing ratio (%)

N/A

Financials

Cantargia is a clinical-stage biotechnology company with lead asset nadunolimab (CAN04) under assessment for several oncology indications. The company has announced that the first triple-negative breast cancer patient has been treated in the Phase II part of the TRIFOUR trial. The Phase Ib portion showed a favourable safety profile of the drug with early signs of efficacy. The Phase II portion is an open-label, randomised trial to compare nadunolimab in combination with chemotherapy agents gemcitabine and carboplatin against the chemotherapy agents alone (expected n=98). We view this as an important milestone for Cantargia and management expects an interim futility analysis of 28 patients to take place in Q423.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2021A 0.0 (366.8) (366.5) (365.80) N/A N/A
2022A 0.0 (377.9) (371.8) (290.43) N/A N/A
2023E 0.0 (302.1) (306.6) (183.58) N/A N/A
2024E 0.0 (286.9) (292.6) (175.20) N/A N/A

Healthcare

Cantargia — Announcement of rights issue

Healthcare

Cantargia — ASCO data do not disappoint

Healthcare

Cantargia — CAN04 progressing on all fronts

Healthcare

Cantargia – executive interview

Healthcare

Cantargia: Edison Open House Healthcare 2022

Healthcare

Cantargia – executive interview

Healthcare

Cantargia – executive interview

Healthcare

Cantargia – Edison Open House interview

Healthcare

Executive interview – Cantargia

Healthcare

Cantargia — Excellent end to the year

Healthcare

Executive interview – Cantargia

Healthcare

Cantargia — Phase IIa set to start in Q418